Chimeric antigen receptor (CAR) T-cell therapy, first approved by the FDA in 2017, is a rapidly growing field in cancer therapy and involves the isolation and activation of T cells from a patient’s blood for ex vivo genetic modification.
The engineered T cells are then infused back into the patient to enable T cell–mediated cytotoxicity as treatment. CRISPR-Cas9 is one of the most commonly leveraged nonviral editing tools for engineering T cells for therapeutic applications. Thermo Fisher now offers the Gibco CTS TrueCut Cas9 Protein for use as an ancillary material in cell and gene therapy applications.
This application note from Thermo Fisher Scientific assesses the performance of the CTS TrueCut Cas9 Protein against a research-grade Cas9 protein to confirm that the manufacturing scale-up of the enzyme had no significant impact on the product performance, indicating that the product can reliably be used for cell and gene therapy development.
Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific